Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT02168777 |
| Title | Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer |
| Recruitment | Terminated |
| Gender | both |
| Phase | Phase Ib/II |
| Variant Requirements | No |
| Sponsors | Bayer |
| Indications | |
| Therapies | |
| Age Groups: | adult |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| New Haven | Connecticut | 06510 | United States | Details | ||
| Detroit | Michigan | 48201 | United States | Details | ||
| Saint Louis | Missouri | 63110 | United States | Details | ||
| Chapel Hill | North Carolina | 27599 | United States | Details | ||
| Houston | Texas | 77030 | United States | Details |